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AbstrAct
Objectives To use routine clinical data to investigate 
survival in dementia with Lewy bodies (DLB) compared 
with Alzheimer’s dementia (AD). DLB is the second most 
common dementia subtype after AD, accounting for around 
7% of dementia diagnoses in secondary care, though 
studies suggest that it is underdiagnosed by up to 50%. 
Most previous studies of DLB have been based on select 
research cohorts, so little is known about the outcome of 
the disease in routine healthcare settings.
setting Cambridgeshire & Peterborough NHS Foundation 
Trust, a mental health trust providing secondary mental 
health care in England.
sample 251 DLB and 222 AD identified from an 
anonymised database derived from electronic clinical 
case records across an 8-year period (2005–2012), with 
mortality data updated to May 2015.
results Raw (uncorrected) median survival was 3.72 
years for DLB (95% CI 3.33 to 4.14) and 6.95 years for 
AD (95% CI 5.78 to 8.12). Controlling for age at diagnosis, 
comorbidity and antipsychotic prescribing the model 
predicted median survival for DLB was 3.3 years (95% 
CI 2.88 to 3.83) for males and 4.0 years (95% CI 3.55 to 
5.00) for females, while median survival for AD was 6.7 
years (95% CI 5.27 to 8.51) for males and 7.0 years (95% 
CI 5.92 to 8.73) for females.
conclusion Survival from first presentation with cognitive 
impairment was markedly shorter in DLB compared with 
AD, independent of age, sex, physical comorbidity or 
antipsychotic prescribing. This finding, in one of the largest 
clinical cohorts of DLB cases assembled to date, adds to 
existing evidence for poorer survival for DLB versus AD. 
There is an urgent need for further research to understand 
possible mechanisms accounting for this finding.
IntrOductIOn
background/rationale
Dementia with Lewy bodies (DLB) accounts 
for around 7% of dementia cases in secondary 
care according to clinic-based prevalence 
studies,1 although other studies have suggested 
that DLB is underdiagnosed, with up to 50% of 
cases missed.2 
Health services in the UK National Health 
Service (NHS) comprise primary care (provided 
in general practice settings), secondary care 
(specialist care including outpatient services 
such as memory clinics and inpatient services 
such as acute psychiatric wards) and tertiary 
care (subspecialist care provided in selected 
centres). In UK practice new dementia diag-
noses are usually made by clinicians working 
in secondary care, most commonly old-age 
psychiatrists and neurologists. There is no 
clear demarcation between which specialties 
diagnose which dementia subtypes, and new 
diagnoses are made in a range of secondary 
care settings.
Compared with Alzheimer’s dementia (AD), 
studies have suggested that DLB cases have 
accelerated cognitive decline, more comorbid 
conditions, a higher mortality rate, greater 
service use and poorer quality of life.3–8 Until 
recently, it was generally accepted that DLB 
was more common in males than females, 
though recent studies have challenged this.1
Most previous studies of DLB have been 
based on select research cohorts, so less is 
known about the naturalistic patterns, char-
acteristics and outcomes of the disease in 
routine clinical settings. More recent studies, 
however, have used dementia registry and 
population data to examine subtype specific 
mortality and comorbidity patterns.6–8
The emergence of electronic case records 
and the technology to make these records 
searchable gives the potential to bring 
together larger patient cohorts in order to 
study clinical populations that are otherwise 
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Research
strengths and limitations of this study
 ► Large clinical cohort of dementia with Lewy bodies 
cases.
 ► Study design reflecting clinical conditions.
 ► Cases identified by treating clinician diagnosis; 
therefore, undiagnosed/wrongly diagnosed cases 
may have been missed.
 ► Possibility of bias introduced by secondary care 
study setting.
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difficult to identify. Routine clinical data can now be used 
to track referral and diagnostic patterns in order to char-
acterise diagnostic trends better and to use these data to 
inform development of dementia services.
Objectives
This study aimed to identify a retrospective natural-
istic cohort of patients with a diagnosis of DLB within a 
secondary care sample, describe their demographic and 
clinical characteristics and measure survival, using as 
a comparator group a cohort of patients with AD diag-
nosed over the same time period.
MethOds
study design
A retrospective cohort design was used. The cohort 
was identified from the electronic clinical records of 
Cambridge and Peterborough NHS Foundation Trust 
(CPFT), which provides secondary mental healthcare 
to a local population of approximately 900 000 people 
in the UK.
CPFT’s electronic records from 2005 to 2012 were 
deidentified using Case Records Interactive Search 
software9 to create a research database. The deidenti-
fication process removes identifying information such 
as names and addresses from the records and assigns 
an arbitrary patient-specific research identifier. Such 
anonymised electronic records methods have been 
successfully used in secondary mental healthcare to 
examine variables such as mortality10 11 and incidence 
of treatment complications.12
Data entered onto the system by CPFT clinicians 
(mental health specialists including doctors, nurses, 
allied health specialities and social workers) related 
only to patients currently under the care of secondary 
mental health services, although they may have been 
cared for in a number of settings (eg, outpatient 
clinics, inpatient units and in the community). Some 
data entered onto the clinical system were recorded 
in a systematic and structured way (eg, date of birth), 
while others were recorded as required clinically and 
in free text (eg, contemporaneous case records, cogni-
tive scores and medical history). Frequency of data 
entry was guided by clinical necessity and not further 
specified. The corresponding research database there-
fore contains some structured data fields (including 
demographic variables and diagnosis if coded), but the 
majority of clinical information was found within free-
text fields.
Population
All patients with electronic clinical records in CPFT 
between 2005 and 2012 (inclusive) were eligible for 
inclusion in the study. We chose not to include data 
prior to 2005 for reasons relating to implementation of 
electronic document storage.
study sample
Dementia diagnoses in CPFT were made by psychiatrists 
specialising in old-age psychiatry.
All patients with a clinician-recorded diagnosis of DLB 
within this timeframe were included, with a comparator 
cohort of patients with a clinician-recorded diagnosis of 
AD (sampled randomly from all possible such patients; 
see below).
case identification
Key word, phrase and acronym searches based on 
the diagnosis of DLB (eg, ‘Lewy’, ‘LBD’, ‘DLB’) were 
applied to the full dataset. Unique document identi-
fiers containing these key words were extracted, with 
surrounding text containing the key word, phrase or 
acronym. The same process was repeated for AD. Only 
records in which the key words or phrases appeared in 
the initial search were examined further.
An initial manual scan of the extracted text frag-
ments excluded definite non-cases (eg, ‘does not have 
Lewy body dementia’). For the remaining documents, a 
manual search of the anonymised patient record related 
to that document was performed.
Manual case identification was then carried out on the 
records identified by experienced clinicians (AP and VM), 
with knowledge of diagnostic criteria13 14 and symptom 
presentation in dementia. Cases were positively identified 
if a diagnosis had been given by a CPFT clinician and it 
was the most recently recorded diagnosis in the patient 
record (ie, not later changed to another diagnosis that 
excluded the diagnosis of interest). Clinician-identified 
cases were then validated against diagnostic criteria for 
DLB and AD, respectively.13 14
Variables
Once cases had been positively identified, demographic, 
clinical and temporal data were extracted from the corre-
sponding anonymised case record. Basic demographic 
data (eg, date of birth and gender) were extracted auto-
matically using Structured Query Language queries, and 
clinical data were extracted by clinicians manually by 
searching the anonymised case records.
Cognitive status was measured using the Mini-Mental 
State Examination (MMSE).15 The MMSE score closest 
to recorded diagnosis was taken as the MMSE score at 
diagnosis.
We recorded the date of the first consultation where 
cognitive impairment was recorded as a problem and the 
date of diagnosis by month and year.
Physical comorbidy was measured using the Charlson 
comorbidity index.16 This measure contains 19 catego-
ries of comorbidity and can be used to predict 10-year 
mortality for patients who have a range of comorbid 
conditions.17 Each comorbid condition is assigned a 
score of 1, 2, 3 or 6 depending on the associated mortality 
risk; for example, metastatic cancer is assigned a score 
of 6. The Charlson score has been used in a previous 
study of comorbidity profile in DLB versus AD, although 
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Table 1 Comparison of demographic and clinical data between DLB and AD cohorts
Characteristic DLB (n=251) AD (n=222) χ2 or F test statistic p Value
Gender
  Female 129 (51.4%) 139 (62.6%) χ21 = 6.04 0.01
  Male 122 83
Age at first presentation with cognitive 
impairment (years)
78.8 (SD 7.7) (n=251) 79.5 (SD 8.8) (n=200) F1,449 =2.51 0.11
Age at diagnosis (years) 79.3 (SD 7.6) 80.2 (SD 8.8) F1,471 =1.32 0.25
MMSE score at diagnosis 20.1 (SD 5.5) (n=183) 20.6 (SD 4.9) (n=172) F1,353 <1 0.41
Charlson comorbidity index at diagnosis
  Low comorbidity (score ≤2) 183 (72.9%) 158 (71.2%) χ21 = 0.18 0.67
  High comorbidity (score >2) 68 64
Medications prescribed
  Antipsychotic (neuroleptic) drugs 103 (41.0%) 32 (14.4%) χ21 = 39.6 <0.0001
  Parkinson’s disease drugs 93 (37.1%) 0 (0%) χ21 = 102.39 <0.0001
  Antidementia drugs 152 (60.6%) 139 (62.6%) χ1 = 0.21 0.65
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination.
the scores used were not weighted by mortality risk.6 
We calculated the score that best reflected the physical 
comorbidities documented in the patient record at the 
time of diagnosis. All cases were assigned at least a score 
of 1 due to their dementia diagnosis as per the Charlson 
scoring algorithm.
Antipsychotic prescribing was recorded as present if 
any such drugs were documented as being prescribed 
at any time in the clinical record. Antidementia drug 
prescribing was recorded as present if the patient 
had received such a drug (cholinesterase inhibitor or 
memantine) and continued to take it beyond the initia-
tion phase. Parkinson’s disease drug prescribing (dopa-
mine precursor or agonist) was recorded as present if 
documented at any time in the clinical record.
Mortality data in the database were derived from 
automatic updates of the source clinical records from 
the NHS Spine,18 including data for patients who were 
discharged from the service before death. The study 
end date was May 2015.
statistical methods
Baseline demographic and clinical data were analysed 
using Microsoft’s Excel Analysis Toolpak. Within each 
diagnostic group, we calculated the sex ratio, mean 
age at diagnosis, mean MMSE at diagnosis, propor-
tions of patients prescribed antipsychotic and antide-
mentia medications and proportions of those with high 
versus low comorbidity scores on the Charlson index. 
Continuous variables were compared between the 
two diagnostic groups using one-way analysis of vari-
ance (ANOVA); binary variables were compared using 
χ2 tests. Results are presented in table 1.
We analysed survival data using the Cox propor-
tional hazards model, with R V.3.3.019 and the ‘survival’ 
package. We defined each patient’s start time as the 
date (month/year) that they presented with cognitive 
impairment. If this was not known, then the date of 
diagnosis was used instead. The end time was either 
the date of death, or the study end time for surviving 
patients (May 2015, the dataset’s most recent update of 
NHS spine mortality data). Although dates of diagnosis 
were not included if before 2005, some records reported 
date of first presentation with cognitive impairment 
before 2005.
We tested for baseline differences in potential predic-
tors between the AD and DLB groups using one-way 
ANOVA (for continuous variables) or χ2 tests (for 
binary variables).
Survival was predicted using discrete factors of diag-
nosis (AD vs DLB), sex, physical comorbidity (dichoto-
mised as: a ‘low’ Charlson score of ≤2 vs a ‘high’ score 
of >2) and antipsychotic prescribing at any time (yes/
no). The ‘diagnosis’ predictor was allowed to interact 
with each of the other binary predictors (but interactions 
between sex, comorbidity and antipsychotic prescribing 
were not included). Age was included as a continuous 
covariate (not interacting with other predictors). Data 
are displayed using survival (Kaplan-Meier) plots.
In addition to the full model (IC1 in table 2), we tested 
a range of simpler models using the following predic-
tors: (C1) diagnosis; (C2) diagnosis, age and sex, with no 
interactions; (C3) diagnosis, age, sex and frailty, with no 
interactions; and (C4) diagnosis, age, sex, frailty and anti-
psychotic prescribing, with no interactions. We compared 
sequential models using likelihood ratio tests to see if the 
addition of additional predictors was justified. We also 
tested an equivalent set of models (D1–D4 and ID1) using 
the time since diagnosis as the dependent variable, rather 
than the time since presentation with cognitive impair-
ment, to see if the same pattern of results held.
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Patient involvement
Patients were not involved directly in this study, and 
patient level data were not identifiable due to the anony-
misation process. The authors worked closely with a CPFT 
dementia patient and carer advisory group who advised 
on research priorities and agenda setting during the 
project.
results
sample
The initial text word search in the DLB case identifica-
tion process across the entire time period of the data-
base yielded 2276 separate clinical documents (eg, clinic 
letters) pertaining to 983 unique patient records. Manual 
searching of these records to exclude non-cases yielded 
a total of 304 individual cases in the database. Over the 
8-year study period (2005–2012), there were 251 new 
diagnoses of DLB made within CPFT.
For the AD cohort, the initial text search yielded 21 424 
unique clinical documents pertaining to 7442 unique 
patient records. If a similar case-finding ratio is assumed, 
then there would be approximately 2304 cases of AD in 
the database in total. Data were gathered for 254 randomly 
selected cases of AD for comparison (approximately 10% 
of expected total cases). Of these, 222 were newly diag-
nosed between 2005 and 2012, and these were used as the 
comparator group.
Main results
In the AD cohort, 153 (69%) patients had been given a 
diagnosis of dementia in Alzheimer’s disease, 66 (30%) 
had been given a diagnosis of atypical or mixed AD and 
3 (1%) had been given a diagnosis of AD with early 
onset. In the DLB cohort, all the patients had been 
given a diagnosis of DLB (rather than a dementia in 
Parkinson’s disease or mixed DLB) diagnosis. We vali-
dated the clinician-diagnosed DLB cases against stan-
dard diagnostic criteria and found that 244/251 (97%) 
had probable or possible DLB, and of those, 58% were 
probable and 39% were possible. All of the patients in 
the AD cohort met the diagnostic criteria for AD.
In the DLB cohort, there was an overall year-on-
year increase in new diagnoses across the 8-year study 
period. An upwards trend in annual diagnoses was also 
found in the AD group.
There were no differences between the DLB and 
AD groups in mean age at presentation with cognitive 
impairment or diagnosis, mean MMSE at diagnosis, phys-
ical comorbidity burden at diagnosis or antidementia 
drug prescribing. There was, however, a significantly 
higher ratio of females to males in the AD compared 
with the DLB group. There were also significant differ-
ences between groups in antipsychotic prescribing and 
Parkinson’s drug prescribing, both being higher in the 
DLB group (see table 1).
Age at diagnosis did not differ significantly between 
groups (mean±SD: AD: 80.2±8.8 years, n=222; DLB: 
79.3±7.6 years, n=251) (one-way ANOVA, F1,471=1.32, 
p=0.25). Age residuals deviated from a normal distri-
bution (Shapiro-Wilk test, W=0.968, p=1.33 × 10–8), and 
a quantile-quantile (Q–Q) plot showed that age exhib-
ited some minor negative skew and was somewhat lepto-
kurtic; ANOVA is robust to this situation.20
MMSE at diagnosis did not differ significantly between 
groups (mean±SD: AD: 20.6±4.9, n=172; DLB 20.1±5.5, 
n=183) (one-way ANOVA, F<1, NS). MMSE residuals 
deviated from a normal distribution (Shapiro-Wilk 
test, W=0.967, p=3.27 × 10–7), and a Q–Q plot showed 
that MMSE also exhibited some minor negative skew, 
although the distribution was very close to mesokurtic 
(Pearson kurtosis 3.2); again, ANOVA is robust to this 
situation.20
Age at presentation with cognitive impairment was 
available for all patients with DLB and 200/222 patients 
with AD. There were no group differences (see table 1). 
As for age at diagnosis, residuals for age at cognitive 
impairment deviated from a normal distribution (Shap-
iro-Wilk W=0.969, p<0.001) by being slightly negatively 
skewed (skew –0.77) and leptokurtic (Pearson kurtosis 
4.29) to which ANOVA is robust.20 In the survival analysis 
below, ‘age at presentation with cognitive impairment’ 
is replaced with ‘age at diagnosis’ for those subjects for 
whom age at presentation with cognitive impairment 
was unavailable (see Methods).
survival analysis
Median survival for DLB was significantly shorter in the 
DLB group compared with the AD group. Raw (uncor-
rected) median survival was 3.72 years for DLB (95% CI 
3.33 to 4.14) and 6.95 years for AD (95% CI 5.78 to 
8.12). For males, median survival in DLB was 3.57 years 
(95% CI 3.24 to 4.14) and in AD 6.46 years (95% CI 
5.42 to 8.12). For females median survival in DLB was 
3.81 years (95% CI 3.36 to 4.50) and in AD 7.03 years 
(95% CI 5.92 to 8.73).
The best fit model for survival from date of presen-
tation with cognitive impairment included diagnosis, 
age, sex, frailty and neuroleptic prescribing with sex 
and diagnosis, frailty and diagnosis and neuroleptic 
prescribing and diagnosis included as interacting 
terms (see table 2). The difference in survival from 
time of presentation with cognitive impairment was not 
explained by any differences in sex, age, comorbidity 
burden or antipsychotic prescribing. In the overall 
model, there was a large effect of diagnosis (HR 3.04 
for DLB vs AD, Z=5.2, p<0.001). As expected, there was 
an effect of age (HR of 1.06 for every year older; Z=6.77, 
p<0.001), although ages were not different between the 
diagnostic groups (table 1) and the effect of diagnosis 
was found over and above the effect of age.
There was no main effect of sex (Z=0.50, NS) and no 
interaction between diagnosis and sex (Z=0.95, NS). 
There was an effect of comorbidity that interacted 
with diagnosis (Z=‒2.17, p=0.030), but this effect was 
only seen in the AD group (subanalysis for AD with 
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Figure 1 Survival in dementia with Lewy bodies (DLB) versus Alzheimer’s dementia (AlzD). Bands indicate 95% CIs for the 
cumulative hazard. F, female; M, male.
sex, antipsychotic prescribing, comorbidity and age 
as predictors: effect of comorbidity, HR 1.82, Z=2.86, 
p=0.004) and not in the DLB group (similar analysis; 
Z=0.18, NS). The effect of antipsychotic prescribing 
did not reach significance, either as a main effect (HR 
1.60, Z=1.94, p=0.053) or as an interaction with diag-
nosis (Z=‒1.85, p=0.065), although the trend was for 
a numerically greater adverse effect of antipsychotics 
in AD (subgroup analysis as before, HR=1.60, Z=1.92, 
p=0.055) than in DLB (HR=0.94, Z=‒0.37, p=0.71).
Survival by diagnosis and sex is presented in figure 1.
At the global mean values for age at diagnosis (79.4 
years), comorbidity (dichotomised frailty index 0.279) 
and antipsychotic prescribing (0.285), the model 
predicted median survival for DLB was 3.3 years 
(95% CI 2.88 to 3.83) for males and 4.0 years (95% CI 
3.55 to 5.00) for females, while median survival for AD 
was 6.7 years (95% CI 5.27 to 8.51) for males and 7.0 
years (95% CI 5.92 to 8.73) for females.
In order to ascertain if there was any bias introduced 
by choosing the start time as date of presentation with 
cognitive impairment rather than date of diagnosis, we 
repeated the survival analysis using date of diagnosis 
as the start time. We found few differences between 
the results of the two analyses (see table 2).
dIscussIOn
Key results
Survival was markedly poorer for the DLB cohort than 
the AD cohort. This difference was not explained by 
sex, stage of dementia or age at presentation, comor-
bidity burden or drug prescribing. Our study showed 
a differential survival between AD and DLB of around 
3 years for both males and females with survival 
being shorter in males in both cohorts. In our study, 
men with DLB had the poorest survival numerically, 
followed by women with DLB, men with AD then 
women with AD; however, the sex differences were 
not significant in the full adjusted model (table 2). In 
contrast, a previous study3 found women with DLB to 
have the poorest survival, followed by men with DLB, 
men with AD, then women with AD. Previous studies in 
DLB have shown survival of 5.5–7.7 years from disease 
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onset and 1.9–6.3 years from diagnosis.7 Our findings 
are therefore in line with those from other mortality 
studies in DLB as the time of first presentation would 
be expected to be between symptom onset and diag-
nosis. Recent national data on dementia mortality 
in the Mental Health Minimum Data Set (MHMDS) 
shows a median survival of 3.5 years from diagnosis 
with cognitive impairment or dementia at ‘moderate 
need’ (not further defined) with shorter survival times 
when needs are high or very high.21 This is somewhat 
surprising given that the mortality of the lowest needs 
group reported in the MHMDS sample is in line with 
the poorer surviving of our two cohorts. The MHMDS 
does not report the diagnostic breakdown of the popu-
lation studied nor does it report any adjustment for 
other potential confounders.
We did not find a significant association between anti-
psychotic prescribing and mortality, which was surprising 
especially in the DLB cohort where there is well-charac-
terised sensitivity to antipsychotic medication.22
Comorbidity burden was specifically associated with 
mortality in the AD group only, which was surprising 
given that other studies have found that increased comor-
bidity burden is associated with increased risk of mortality 
in dementia including DLB in both a research cohort3 
and a whole population epidemiological study.8 In our 
study, we used a dichotomised comorbidy index of ‘low’ 
versus ‘high’ rather than the mean Charlson score, more 
detailed symptom profiles3 6 or number of prescribed 
medications.8 Where finer grained physical comorbidity 
data have been included in analyses, resting tremor was 
the only single physical comorbidity related to survival 
and was found to be a protective factor.3 When comor-
bidity profiles have been compared between DLB and 
AD cohorts, overall comorbidity burden has been shown 
to be higher in DLB, from the time of diagnosis, with 
increased cerebrovascular comorbidity.6 In contrast, we 
found that at the time of diagnosis, there was little differ-
ence between the two groups (though we were not able 
gather data to the same level of detail).
This study further strengthens the findings from a 
number of studies that survival is poorer in DLB than AD, 
although in our cohort, this finding was not accounted 
for by other factors measured, including physical comor-
bidity burden, suggesting that there may be an intrinsi-
cally higher rate of mortality in DLB than AD.
Further work is needed both to examine factors asso-
ciated with this excess mortality in DLB in this and other 
cohorts, so that high-risk subjects can be identified, and 
to elucidate potential mechanisms that may underpin 
this increase to inform intervention studies. A number 
of potential factors have been identified, although often 
from small studies. These include clinical features such as 
the presence of autonomic symptoms and hallucinations, 
and pathological features such as increased cerebrospinal 
fluid tau and apolipoprotein E4.7
strengths
Clinical information was extracted from the electronic 
case records by experienced clinicians, to a clear protocol, 
and validated against accepted diagnostic criteria. The 
advantage of identifying a large retrospective sample is 
that the characteristics of the sample are reflective of a 
clinical population. The identification of a cohort of AD 
cases in the same service during the same time frame 
allowed for comparisons to be made under similar clin-
ical conditions.
limitations
This study focused on identification of two clinically diag-
nosed dementia subtypes, DLB and a comparison group 
with AD, with a complete cohort of DLB cases identified 
over an 8-year period. Cases were primarily identified as 
DLB or AD in the study if they were assigned the diag-
nosis by the treating clinician and then validated against 
diagnostic criteria. It is possible, though, that a small 
number of cases were misclassified and, if a prospective 
case identification strategy had been used, these cases 
would have been assigned a different dementia subtype 
diagnosis. Low diagnostic accuracy23 and comorbidity 
between DLB and AD in dementia24 has previously been 
shown in pathological DLB cohorts. We were also not 
able to extract consistent data on the temporal onset of 
core DLB features. It is therefore possible that a subset 
of patients with more advanced AD were misclassified as 
having DLB based on the core symptom profile. Using 
our methodological approach, we were not able to iden-
tify patients who would have fulfilled criteria for DLB 
but had not been diagnosed with the condition as our 
search strategy relied on text terms associated with the 
diagnostic descriptions. Given the limitations above, the 
difference between the two clinically diagnosed cohorts 
regarding survival is therefore more striking as one might 
expect the differences to be less marked given lower diag-
nostic accuracy in a clinical rather than pathologically 
diagnosed study sample.
The case note design meant that while we were able 
to capture data from a naturalistic cohort accessing 
secondary care, we were not able to ensure the complete-
ness of data that might be acquired in a research sample. 
In particular, we extracted the comorbidity data only from 
what we were able to gather from the patient record and 
we did not have a complete set of MMSE scores at diag-
nosis. In addition, we used MMSE as our primary measure 
of cognitive function, as this was the tool routinely used in 
clinical practice, but this would not have given a complete 
picture of cognitive dysfunction particularly in the DLB 
cohort.
The cohorts analysed in this study were selected based 
on their diagnoses being made within a specified time 
frame and were not more specifically matched, although 
every attempt was made to minimise bias in identifica-
tion of the comparator cohort, and subsequent analysis 
found few significant differences in demographic and 
clinical characteristics. It is possible, though, that the 
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study outcome would have been different if a more robust 
matching strategy had been employed.
The study sample comprised two diagnostic groups 
over a specified time period in a secondary mental health-
care setting. It is possible that the findings of the study 
do not reflect the total populations with these diagnoses. 
Diagnosis in a secondary care setting may reflect greater 
symptom severity, for example, although in the UK, the 
great majority of new diagnoses of dementia (and subse-
quent initiation of treatment) are currently made in 
secondary care following GP or specialist referral.25 The 
mean MMSE at diagnosis for both groups was in the mild-
to-moderate range of severity of cognitive impairment, 
with similar SD. The study findings may be limited by not 
identifying patients at earlier stages of disease, although 
patients referred into secondary care (especially to 
community mental health teams) are likely to be referred 
with functional decline or other related difficulty, which 
will usually occur beyond the earliest stages of disease. 
Previous studies of mortality in DLB have reported similar 
baseline mean MMSE scores.6 8
The retrospective nature of the study meant that accu-
rate estimation of timing of symptom onset was not 
possible, limiting our ability to report duration of illness 
accurately. To minimise any bias introduced by differen-
tial timing of diagnoses between the groups (although 
there was no evidence in the baseline data to suggest this 
was the case), we based the primary survival analysis on 
the date of first presentation with cognitive impairment, 
rather than the date of diagnosis, but reanalysis using 
date of diagnosis produced similar results.
Interpretation
The underlying reason for the difference in mortality rates 
between the DLB and AD cohorts remains unclear, but 
this study adds to the existing evidence showing a higher 
mortality rate for DLB than AD, although not accounted 
for by other factors including comorbidity burden.
Generalisability
CPFT is a relatively small mental health trust, but because 
the methodology used identified a naturalistic clinical 
sample, it is likely that the cohorts identified are repre-
sentative of a wider secondary care population with 
dementia. A number of other mental health trusts have or 
are developing the capability to use anonymised clinical 
records for research. The methodology used to select the 
cohorts for this study could be repeated on these trusts’ 
clinical records and findings compared with determine 
whether our study’s findings generalise across other clin-
ical populations.
It was not possible to gather consistent or complete 
data on ethnicity, education level and level of depriva-
tion. If we had been able to gather these data, it may have 
been possible to discuss in more detail how the results 
of this study may be comparable with other dementia 
populations. Considering the CPFT patient population as 
a whole, however, the Trust serves a fast-growing, ageing 
and diverse population with significant inequalities,26 
which are likely to be reflected in our study cohort.
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